Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03576625
Other study ID # HC-NNHPD-230190
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 10, 2018
Est. completion date December 2018

Study information

Verified date September 2017
Source Réseau de Santé Vitalité Health Network
Contact Marc Surette, PhD
Phone 1-506-858-4293
Email marc.surette@umoncton.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect of Buglossoides oil emulsion on the intensity of recent chronic knee and hip pain, on plasma and mononuclear blood cells fatty acid profiles and on whole blood Eicosapentaenoic acid production will be investigated.


Description:

This study will document the impact of an emulsion of Buglossoides oil on the intensity of recent chronic knee and hip pain. Secondly, the impact of consuming Buglossoides oil on plasma and leukocyte fatty acid profiles will be investigated, thus providing clinical evidence on the efficacy of an emulsion of Buglossoides oil in increasing EPA content. Lastly, a comprehensive analysis of whole blood eicosanoid production following supplementation will provide data on the potential for Buglossoides oil to modulate immune function.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Men or non-pregnant women, using an effective form of birth control (such as oral contraceptives, injectable contraceptives or the barrier method such as a intrauterine device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a spermicide or a sponge with a spermicide) for at least 3 months prior to entry into the study and continuing during participation in the study.

2. 18 to 65 years of age, inclusive.

3. Body mass index (BMI) 18 - 39.9 kg/m2

4. Subject has recent (less than 6 months) current chronic (having lasted more than two weeks) knee (one or both) and/or hip pain that is not the result of an acute injury. Pain intensity is 20 mm or higher using a Visual Analog Scale ranging from 0-100 mm.

5. Subject has no planned knee or hip surgery.

6. Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit.

7. The subject will not modify smoking habits during supplementation period.

8. No significant medical conditions that in the opinion of the qualified physician, would preclude the subject's participation in the study.

9. Signed informed consent.

10. Willing to follow all study procedures including study visits, fasting blood draws, stable body weight, normal eating habits, current activity level, and compliance with study preparation.

11. Willing to not consume fish, crustaceans and shellfish for the duration of the study.

12. Willing to avoid taking anti-inflammatory medications (analgesics and NSAIDs) for 24 hours prior to Visits 2 and 5.

Exclusion Criteria:

1. Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. Method of contraception must be recorded in the case report file.

2. Has had a diagnosis of rheumatoid arthritis.

3. Individual has a condition the study physician believes would interfere with the participant's ability to provide informed consent, comply with his responsibilities during the study, which might confound the interpretation of the study results or put the person at undue risk.

4. Self-reported medical conditions including an active peptic ulcer, inflammatory bowel disease, or gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery that could influence absorption, metabolism or excretion of the study supplement.

5. History or presence of significant, renal, hepatic, gastrointestinal, pulmonary, biliary, neurological or endocrine disorders.

6. History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers (e.g. basal or squamous cell carcinoma of the skin).

7. Clinically significant abnormal laboratory test results including but not limited to LDL-cholesterol = 4.1mM, triglyceride levels =3.95mM, fasting creatinine = 1.5 mg/dL, ALT or AST = 1.5X the upper limit of normal.

8. Currently being treated for angina, arrhythmia and/or congestive heart failure. History of myocardial infarction or stroke.

9. Uncontrolled hypertension (resting systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg).

10. Type 1 or 2 diabetes. Fasting glucose = 100 mg/dL. HbA1c = 6.0.

11. If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily.

12. History (within 12 months) or current alcohol or substance abuse (no more than 14 consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled spirits).

13. Use of steroidal anti-inflammatory medications (prednisone, etc)

14. Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, prescription formulations of niacin).

15. Unstable use of thyroid medication. Stable, treated hypothyroidism is not an exclusion criteria.

16. Use of any weight loss or lipid metabolism medication/supplement/program (including lipase inhibitors) within 1 month of study period OR weight gain or loss > 2 kg in the past 3 months.

17. Currently taking fish oil or any other omega-3 or omega-6 PUFA supplement/drug within one month of Visit 1 and throughout the study. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, and sardines) more than 2X a month within one month of visit 1 and throughout the study period. Consumption (more than twice a month) of any EPA/DHA enriched foods (e.g. DHA-enriched eggs) within one month of Visit 1. Unwillingness to avoid all fish including shellfish and crustaceans throughout the study period.

18. Use of alpha-linolenic acid-containing seeds and oils such as flax seed, chia seed, perilla seed, hemp, spirulina, walnut, mustard seed or black currant seeds/oil within one month of Visit 1 and throughout the study.

19. Use of an investigational product within the previous 30 days.

20. Has donated blood up to 4 weeks before the start of the study. Not willing to cease being a blood donor during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
High Oleic Sunflower Oil
Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
Buglossoides Oil
Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks

Locations

Country Name City State
Canada Université de Moncton Moncton Nouveau-Brunswick

Sponsors (1)

Lead Sponsor Collaborator
Réseau de Santé Vitalité Health Network

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the nature of pain severity Defined by visual analogue scale (VAS) Baseline, 19, 38, 56 days
Primary Change in the nature of fatigue severity Defined by visual analogue scale (VAS) Baseline, 19, 38, 56 days
Secondary Nature and frequency of analgesic use 56 days
Secondary Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, stiffness and physical function scores Baseline, 19, 38, 56 days
Secondary Plasma eicosapentaenoic concentration (EPA) Expressed as umol/L plasma Baseline and day 56
Secondary Plasma 20:4n-3 Expressed as umol/L plasma Baseline and day 56
Secondary Plasma docosapentaenoic acid Expressed as umol/L plasma Baseline and day 56
Secondary Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids Baseline and day 56
Secondary Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids Baseline and day 56
Secondary Eicosanoid profile following ex vivo whole blood immune challenge Baseline and day 56
See also
  Status Clinical Trial Phase
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Completed NCT06049303 - Paraffin Wax Bath With Joint Mobilization Technique in Post-traumatic Stiff Knee N/A
Not yet recruiting NCT05062499 - The Effects of Home Use of Transcutaneous Electrical Nerve Stimulation on People With Knee OA and or Chronic Knee Pain N/A
Completed NCT03998813 - Chronic Pain and Functional Prognosis After Total Knee Replacement: Continuous Locoregional Analgesia by Catheter to the Femoral Triangle Versus Tissue Infiltration as Part of an Improved Rehabilitation After Surgery Approach N/A
Not yet recruiting NCT06466330 - Efficacy of Microparticle Geniculate Artery Embolization in Total Knee Prosthesis Patients With Pain Resistant to Medical Treatment. A Prospective Randomized Controlled Trial N/A
Active, not recruiting NCT03211663 - Performance of MOTO Medial® Unicompartmental Knee Arthroplasty
Completed NCT04146311 - Effect of Short-term Motor Training on Accuracy and Precision of Knee Movement in Human With and Without Knee Pain N/A
Completed NCT03364088 - Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia N/A
Recruiting NCT06197958 - Comparison of Concentric-eccentric Exercises in Patellofemoral Pain Syndrome N/A
Recruiting NCT06239649 - The Effect of RF Genicular Nerve Block Applied in the Preoperative Period on Fast-track Total Knee Arthroplasty
Completed NCT03545048 - Effects of Internet / Web-based Exercises on the Population With Knee Arthritis N/A
Recruiting NCT05596591 - Focused Extracorporeal Shockwave Therapy for Knee Arthritis N/A
Completed NCT05551000 - Functional Training to Improve Everyday Performance in Elderlies N/A
Active, not recruiting NCT05908942 - Genicular RFT vs Phenol Management in Patients With Knee Osteoarthritis
Recruiting NCT04989023 - Clinical Applications of Blood Flow Restriction and Rehabilitation Outcomes N/A
Completed NCT03337243 - Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis N/A
Terminated NCT04620525 - Cognition, Pain and Wellbeing
Completed NCT04443452 - Molecular Pathways Involved in Knee Pain
Recruiting NCT04148807 - Effectiveness of a Walking Intervention on Impact Loading and Pain N/A
Recruiting NCT06094660 - RFA or Chemical Neurolysis of the Genicular Nerves Compared to Conservative Treatment for Knee Pain Caused by OA N/A